+11.4%
BLK vs MRNA
+909.7%
-898.3%
-20.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.4% | -6.5% | +2.2% | -4.3% |
| 7D | -0.5% | +8.4% | -8.9% | -0.6% |
| 30D | +8.5% | +28.8% | -20.4% | +7.9% |
| 3M | +3.8% | +329.2% | -325.4% | -0.8% |
| 6M | +12.8% | +416.9% | -404.1% | +4.4% |
| YTD | +11.2% | +718.8% | -707.6% | -2.9% |
| 1Y | +11.4% | +924.9% | -913.5% | -8.8% |
| All | +11.4% | +909.7% | -898.3% | -8.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling